Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Coupang Still Needs to Prove Its Worth to Investors

By Chris Lau, InvestorPlace Contributor

Investors' patience with CPNG stock appears to be wearing thin as the company invests heavily in growth but fails to turn a profit.

Why DraftKings Is Out of Favor Despite Its Strong Prospects

By Chris Lau, InvestorPlace Contributor

DraftKings has a fair value of $11, which may change to the upside if it earns a profit sooner than the model suggests.

Teladoc Stock Is Due for a Major Upside Reversal

By Chris Lau, InvestorPlace Contributor

Teladoc is worth at least $110 a share assuming its revenue grows at historical rates for the next few years.

Why CrowdStrike Stock Is the Best of Breed Growth Holding

By Chris Lau, InvestorPlace Contributor

CrowdStrike is unjustifiably nearing a 52-week low as panicked investors dump any stock they view as overvalued.

7 Meta Stocks to Buy after Take-Two Buys Zynga

By Chris Lau, InvestorPlace Contributor

The metaverse will grow in the next decade, as Take-Two announces a big acquisition. Expect meta stocks to rise on more news.

Load More